Tag: Multiple Sclerosis
Fatigue Correlates With Disability in Patients With Relapsing-Remitting MS
Lower disability, better physical condition, higher daily-living activity predict lower fatigue
2001 to 2020 Saw Shift in Rx for Disease-Modifying Therapy for Multiple Sclerosis
Oral disease-modifying therapies dominated new initiations by 2020 to 62.3 percent
Early Treatment of Demyelination Events Cuts Long-Term Disability in MS
Reduced risk for reaching EDSS 3.0, secondary progressive MS, sustained disease progression seen with very early treatment
Genes Identified in Association With Multiple Sclerosis Severity
Significant association identified with rs10191329 in the DYSF-ZNF638 locus, with risk allele shortening time to needing walking aid
Pro-Inflammatory Diet Linked to Worsening Relapse Rate in MS
Association seen between energy adjusted dietary inflammatory index score and fluid-attenuated inversion recovery lesion volume
Rituximab Not Noninferior to Ocrelizumab for Relapsing-Remitting MS
Cumulative hazard of relapses higher among patients treated with rituximab versus ocrelizumab
Whites Have Highest Prevalence of Multiple Sclerosis in the United States
Highest prevalence seen in those aged 45 to 64 years; prevalence also increased with each degree of latitude
AAN: Teriflunomide Reduces Clinical Events in Radiologically Isolated Syndrome
Significant reduction seen in clinical events with teriflunomide; nonsignificant reduction noted in Gd+ lesions, new or enlarging T2 lesions
Sleep Disorders Contribute to Cognitive Decline in Multiple Sclerosis
Insomnia, sleep apnea explain roughly 10 to 34 percent of the relationship between multiple sclerosis and cognitive dysfunction
MS Relapse Rate Not Increased After Fertility Treatments
Mean annualized relapse rate not different before versus after controlled ovarian stimulation
